drugset / Trial / NCT01687920

Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets

NCT01687920

Phase 1 Completed 25 enrolled Bayer
RandomizedCrossoverOpen-labelOther

Summary

This study should estimate the dose proportionality of BAY94-8862 IR tablets.

Timeline

Start
2012-09-17
Primary completion
2012-11-28
Completion
2013-03-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Finerenone Small molecule 1.25 mg Oral
Subject Finerenone Small molecule 2.5 mg Oral
Subject Finerenone Small molecule 5 mg Oral
Subject Finerenone Small molecule 7.5 mg Oral
Subject Finerenone Small molecule 10 mg Oral

Indications